Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T21291
(Former ID: TTDI02017)
|
|||||
| Target Name |
Plasmodium Apical membrane protein (Malaria AMA-1)
|
|||||
| Synonyms |
Merozoite surface antigen; Apical membrane antigen 1; AMA1; AMA-1
Click to Show/Hide
|
|||||
| Gene Name |
Malaria AMA-1
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Malaria [ICD-11: 1F40-1F45] | |||||
| Function |
Involved in parasite invasion of erythrocytes.
Click to Show/Hide
|
|||||
| BioChemical Class |
Apicomplexan parasites AMA1
|
|||||
| UniProt ID | ||||||
| Sequence |
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQKSDVYHPINEHREHPKEYQYPLHQEHT
YQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIE EVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSNTTFLTPVATGNQYLKDGG FAFPPTEPLMSPMTLDEMRHFYKDNKYVKNLDELTLCSRHAGNMIPDNDKNSNYKYPAVY DDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAKDISFQNYTYLSKNVVDNWEK VCPRKNLQNAKFGLWVDGNCEDIPHVNEFSAIDLFECNKLVFELSASDQPKQYEQHLTDY EKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNTETQKCEIFNVKPTCLI NNSSYIATTALSHPIEVEHNFPCSLYKNEIMKEIERESKRIKLNDNDDEGNKKIIAPRIF ISDDKDSLKCPCDPEIVSNSTCNFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKP TYDKMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDEPQHYGKSNSRNDEMLDPEA SFWGEEKRASHTTPVLMEKPYY Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | AdCh63 AMA1 | Drug Info | Phase 1/2 | Malaria | [2] | |
| 2 | DNA-Ad | Drug Info | Phase 1/2 | Malaria | [3] | |
| 3 | PfAMA-1 | Drug Info | Phase 1 | Malaria | [4] | |
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014 Sep 11;9(9):e106241. | |||||
| REF 2 | ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT00870987) Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT00431808) Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]). U.S. National Institutes of Health. | |||||
| REF 5 | Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite devel... J Cell Sci. 2003 Sep 15;116(Pt 18):3825-34. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.